首页> 美国卫生研究院文献>Scientific Reports >Predicting short-term survival after liver transplantation on eight score systems: a national report from China Liver Transplant Registry
【2h】

Predicting short-term survival after liver transplantation on eight score systems: a national report from China Liver Transplant Registry

机译:在八种评分系统上预测肝移植后的短期存活:中国肝移植注册中心的国家报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To compare the performance of eight score systems (MELD, uMELD, MELD-Na. iMELD, UKELD, MELD-AS, CTP, and mCTP) in predicting the post-transplant mortality, we analyzed the data of 6,014 adult cirrhotic patients who underwent liver transplantation between January 2003 and December 2010 from the China Liver Transplant Registry database. In hepatitis B virus (HBV) group, MELD, uMELD and MELD-AS showed good predictive accuracies at 3-month mortality after liver transplantation; by comparison with other five models, MELD presented the best ability in predicting 3-month, 6-month and 1-year mortality, showing a significantly better predictive ability than UKELD and iMELD. In hepatitis C virus and Alcohol groups, the predictive ability did not differ significantly between MELD and other models. Patient survivals in different MELD categories were of statistically significant difference. Among patients with MELD score >35, a new prognostic model based on serum creatinine, need for hemodialysis and moderate ascites could identify the sickest one. In conclusion, MELD is superior to other score systems in predicting short-term post-transplant survival in patients with HBV-related liver disease. Among patients with MELD score >35, a new prognostic model can identify the sickest patients who should be excluded from waiting list to prevent wasteful transplantation.
机译:为了比较八个评分系统(MELD,uMELD,MELD-Na。iMELD,UKELD,MELD-AS,CTP和mCTP)在预测移植后死亡率方面的性能,我们分析了6014例接受肝硬化的成人肝硬化患者的数据在2003年1月至2010年12月间从中国肝移植注册数据库中进行移植。在乙型肝炎病毒(HBV)组中,MELD,uMELD和MELD-AS在肝移植后3个月的死亡率方面显示出良好的预测准确性。与其他五个模型相比,MELD在预测3个月,6个月和1年死亡率方面表现出最好的能力,显示出比UKELD和iMELD更好的预测能力。在丙型肝炎病毒和酒精组中,MELD和其他模型之间的预测能力没有显着差异。不同MELD类别的患者生存率在统计学上有显着差异。在MELD评分> 35的患者中,一种基于血清肌酐,需要进行血液透析和中度腹水的新预后模型可以识别出最病的模型。总之,在预测HBV相关肝病患者的短期移植后存活率方面,MELD优于其他评分系统。在MELD评分> 35的患者中,一种新的预后模型可以识别应被排除在候诊名单之外的最病患者,以防止浪费性移植。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号